Indications

Diabetes

  • 50+ clinical sites in Germany, Poland, Bulgaria, Romania, India
  • 100+ investigators in diabetes research
  • Completion of two clinical programs with recombinant Insulins

Diabetes type 1 and type 2

  • six phase III trials in 2100 type 1 and type 2 diabetes patients
  • immunogenicity trials
  • clamp trials

Diabetes patients with foot ulcer

  • Phase II trial in 45 patients